AR046320A1 - STABILIZED PHARMACEUTICAL COMPOSITIONS OF DIBENZO-OXEPINA. - Google Patents

STABILIZED PHARMACEUTICAL COMPOSITIONS OF DIBENZO-OXEPINA.

Info

Publication number
AR046320A1
AR046320A1 ARP040104051A ARP040104051A AR046320A1 AR 046320 A1 AR046320 A1 AR 046320A1 AR P040104051 A ARP040104051 A AR P040104051A AR P040104051 A ARP040104051 A AR P040104051A AR 046320 A1 AR046320 A1 AR 046320A1
Authority
AR
Argentina
Prior art keywords
dibenzo
oxepina
pharmaceutical compositions
stabilized pharmaceutical
stabilized
Prior art date
Application number
ARP040104051A
Other languages
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR046320A1 publication Critical patent/AR046320A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)

Abstract

Se describe una composición que comprende una dibenzo-oxepina y un acidulante en una cantidad efectiva para estabilización. Composición farmacéutica. Método de tratamiento.A composition comprising a dibenzo-oxepine and an acidulant in an amount effective for stabilization is described. Pharmaceutical composition Treatment method

ARP040104051A 2003-11-06 2004-11-04 STABILIZED PHARMACEUTICAL COMPOSITIONS OF DIBENZO-OXEPINA. AR046320A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51791103P 2003-11-06 2003-11-06

Publications (1)

Publication Number Publication Date
AR046320A1 true AR046320A1 (en) 2005-11-30

Family

ID=34572975

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104051A AR046320A1 (en) 2003-11-06 2004-11-04 STABILIZED PHARMACEUTICAL COMPOSITIONS OF DIBENZO-OXEPINA.

Country Status (4)

Country Link
AR (1) AR046320A1 (en)
PE (1) PE20050487A1 (en)
TW (1) TW200529817A (en)
WO (1) WO2005044255A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1757284A1 (en) * 2005-08-25 2007-02-28 Santhera Pharmaceuticals (Schweiz) AG Use of N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy
EP1842539A1 (en) 2006-04-05 2007-10-10 Santhera Pharmaceuticals (Schweiz) AG Use of N- (dibenz(b,f)oxepin-10-ylmethyl)N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency
WO2014120885A1 (en) * 2013-01-30 2014-08-07 The Johns Hopkins University Treatment of drug abuse by preventing gapdh nitrosylation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL124626C (en) * 1964-06-29
AR008371A1 (en) * 1996-05-30 2000-01-19 Novartis Ag AN ADDITION SALT WITH ACID OF A 10-AMINOALIFATIL-DIBENZ [B, F], OXEPINE, YOUR EMPLOYMENT; PROCEDURE FOR ITS PREPARATION, A 10-AMINOALIFATIL-DIBENZ [B, F] OXEPINE, A PHARMACEUTICAL PREPARATION CONTAINING SUCH SALT OR SUCH OXEPINE AND A PROCEDURE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

Also Published As

Publication number Publication date
TW200529817A (en) 2005-09-16
WO2005044255A1 (en) 2005-05-19
PE20050487A1 (en) 2005-10-07

Similar Documents

Publication Publication Date Title
ES2487496T3 (en) Agent to relieve metabolic syndrome
SE0301882D0 (en) New use I
SE0301888D0 (en) New use VII
DK1715865T3 (en) Therapeutic agent for hyperlipaemia with pitavastatin and eicosapentaenoic acid
BRPI0607402A2 (en) use of pde7 inhibitors to treat neuropathic pain
PA8577901A1 (en) PHARMACEUTICAL FORMULATION
BRPI0714417B8 (en) method for making an oral care, personal care, cleanser and / or home care composition
HK1074592A1 (en) 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AR109263A2 (en) COMPOSITION INCLUDING MOXIDECTINE
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
NO20090157L (en) Ten pyrimidines useful as modulators of ion channels
TW200501947A (en) Stabilized pharmaceutical composition comprising an amorphous active substance
NO20071742L (en) Kinazolins useful as modulators of ion channels
AR044155A1 (en) COMBINATION THAT INCLUDES 2- S- [2 - ({[1- (2 - ETHYLBUTY) CYCLHEXYL) CARBONYL} AMINO) PHENYL] METHYLROPANOTIOATE AND A HMG COA REDUCTASE INHIBITOR
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
FR2848116B1 (en) COSMETIC COMPOSITION COMPRISING A METALLO-PROTEINASE INHIBITOR AND A LIPOPEPTIDE
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
MXPA05000765A (en) 5-aryltetrazole compounds, compositions thereof, and uses therefor.
TW200730190A (en) New combination to treat liver fibrosis
PA8571901A1 (en) NEW PHARMACEUTICAL COMPOSITION
TW200504199A (en) Method of preventing lipids constituting lipid membrane from degradation and use thereof
DE60329326D1 (en) TACE INHIBITORS
AR046320A1 (en) STABILIZED PHARMACEUTICAL COMPOSITIONS OF DIBENZO-OXEPINA.
AR040287A1 (en) PLATFORM FOR TRANSDERMAL FORMULATIONS (PFT)
SE0301883D0 (en) New use II

Legal Events

Date Code Title Description
FB Suspension of granting procedure